Discover
TYRA
Tyra Biosciences, Inc.
25.30
1 x 25.29
1 x 25.39
bid
ask
-
0.95
3.62%
12:36 PM
timesize
| Ytd | -3.77% | |
| 1y | 150.49% |
25.28
day range
26.29
9.96
52 week range
40.65
| Open | 26.25 | Prev Close | 26.25 | Low | 25.28 | High | 26.29 | Mkt Cap | 1.51B |
| Vol | 135.81K | Avg Vol | 844.62K | EPS | -2.40 | P/E | -10.54 | Forward P/E | -8.98 |
| Beta | 0.77 | Short Ratio | 10.26 | Inst. Own | 115.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-13 | 50-d Avg | 30.06 | 200-d Avg | 29.28 | 1yr Est | 51.80 |
| Income Statement | |||
| Operating Expenses | 49.00M | ||
| Research and Development Expense | 39.20M | ||
| Selling, General and Administrative Expense | 9.81M | ||
| Operating Income | -49.00M | ||
| Net Income | -45.56M | ||
| Net Income Common Stock | -45.56M | ||
| Net Income Common Stock (USD) | -45.56M | ||
| Consolidated Income | -45.56M | ||
| Earnings per Basic Share | -0.69 | ||
| Earnings per Basic Share (USD) | -0.69 | ||
| Earnings per Diluted Share | -0.69 | ||
| Earning Before Interest & Taxes (EBIT) | -45.56M | ||
| Earning Before Interest & Taxes (USD) | -45.56M | ||
| Weighted Average Shares | 65.99M | ||
| Weighted Average Shares Diluted | 65.99M | ||
| Balance Sheet | |||
| Cash and Equivalents | 74.72M | ||
| Cash and Equivalents (USD) | 74.72M | ||
| Investments | 280.11M | ||
| Investments Current | 280.11M | ||
| Current Assets | 366.97M | ||
| Property, Plant & Equipment Net | 6.48M | ||
| Total Assets | 383.36M | ||
| Debt Current | 504.00K | ||
| Total Debt | 5.58M | ||
| Current Liabilities | 24.62M | ||
| Debt Non-Current | 5.08M | ||
| Total Liabilities | 29.70M | ||
| Accumulated Retained Earnings (Deficit) | -456.12M | ||
| Accumulated Other Comprehensive Income | -580.00K | ||
| Shareholders Equity | 353.66M | ||
| Shareholders Equity (USD) | 353.66M | ||
| Assets Non-Current | 16.40M | ||
| Total Debt (USD) | 5.58M | ||
| Liabilities Non-Current | 5.08M | ||
| Trade and Non-Trade Payables | 2.33M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 138.00K | ||
| Net Cash Flow from Financing | 2.10M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -11.12M | ||
| Capital Expenditure | -66.00K | ||
| Issuance (Purchase) of Equity Shares | 2.10M | ||
| Net Cash Flow from Investing | 17.85M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | 17.92M | ||
| Net Cash Flow from Operations | -31.08M | ||
| Share Based Compensation | 10.23M | ||